
AN ENANTIOSELECTIVE CONSTRUCTION OF PYRROLIDONES BEARING FUNCTIONALIZED APPENDAGES *VIA* AN ASYMMETRIC INTRA-MOLECULAR MICHAEL REACTION


Yoshiro Hirai, Takashi Terada, Hideko Katoh, Sayuri Sonohara, and Takefurni Momose* Faculty of Pharmaceutical Sciences, Toyama Medical and Pharmaceutical University, Sugitani 2630, Toyama 930-01, Japan


Abstract — The intramolecular Michael reaction of acyclic compounds 9 and 10 to form pyrrolidones is reported. Cyclization of 9 and 10 using (R)-(+)-1-phenylethylamine as a mediator gave the pyrrolidones (+)-11 and (+)-12 in 63% and 65% enantiomeric excess, respectively. When (S)-(-)-1-phenylethylamine was used, (-)-11 and (-)-12 were obtained in similar optical yields, respectively.

The intramolecular Michael reaction is among the most important procedures for the construction of cyclic systems,¹ and an asymmetric version of this procedure could provide us with a powerful tool for the chiral synthesis of various natural products and related compounds.² We have previously reported the design of the functionalized piperidine system 2 as an important key building block for the chiral synthesis of *Rauwolfia* alkaloids and accomplished its preparation from the acyclic compound 1 by employing an asymmetric intramolecular Michael reaction.³ In the context with our ongoing program involving the application of an asymmetric intramolecular Michael reaction to the assembly of optically active ring systems, we became interested in the application to the construction of a heterocyclic five-membered ring system. Thus, we designed a 2-pyrrolidone (3) bearing the ring substituents of *trans* arrangement as a chiral building block for the synthesis of α -allo-kainic acid or *Strychnos* alkaloids. Now, we wish to describe the preparation of both enantiomers of 3 by employing an asymmetric intramolecular cyclization.



The substrates for cyclization were prepared according to the following sequence starting from the secondary atmines 4⁴ and 5.⁵ Treatment of 4 and 5 with (*E*)- β -carbethoxyacrylyl chloride (6)⁶ in ether in the presence of triethylamine gave the amides 7⁷ and 8, which were subjected to the Wacker oxidation⁸ to furnish the ketones 9 and 10 in 86% and 78% overall yield, respectively. Cyclization of 9 was carried out by the treatment with (*R*)-(+)-1-phenylethylamine⁹ in THF in the presence of molecular sieve 5A at 5 °C to afford the pyrrolidone (+)-11,¹⁰ [α]_D²⁶ +24°(CHCl₃), in 63% enantiomeric excess (ee)¹¹ (89% yield). When (*S*)-(-)-1-phenylethylamine¹² was used, (-)-11, [α]_D²⁶ -22.6°(CHCl₃), was obtained in 63% ee (84% yield). The optical yield (ee) of the cyclization was determined by hplc using a chiral column.¹³ The absolute configuration of (-)-11 with methyltriphenylphosphonium iodide in the presence of *n*-butyllithium (*n*-BuLi) gave the olefin 13 in 54% yield. The synthetic pyrrolidone (13), [α]_D²⁶ -24.2°(*c* 0.4, CHCl₃), was identical with an authentic sample, [α]_D²⁶ -28.3°(*c* 0.4, CHCl₃) which was obtained from α -allo-kainic acid through the sequential oxidative decarboxylation,¹⁴ esterification, and *N*-benzylation. Thus, the absolute configuration of (+)-11 is (3*R*, 4*R*) or (3*S*, 4*S*).





Next, we examined the asymmetric Michael reaction of a substrate (10) having an indole moiety. Treatment of 10 with (R)-(+)-1-phenylethylamine under the same conditions as described above gave the pyrrolidone (+)-12 in 65% ee¹⁵ (95% yield). Its enantiomer [(-)-12] was obtained in a similar optical yield by using (S)-(-)-1-phenylethylamine as a chiral amine. The sodium borohydride reduction of (-)-12 followed by the sequential treatment with 1,1'-thiocarbonyldiimidazole¹⁶ and tributyltin hydride (*n*-Bu₃SnH) provided the *N*tryptophylpyrrolidone 15 in 40 % yield from (-)-12.

The pyrrolidone [(-)-11 or (-)-12] produced in this manner would be a useful key building block for α -allokainic acid or *Strychnos* alkaloids.¹⁷ The synthesis of these natural products from (-)-11 and (-)-12 is under investigation.


ACKNOWLEDGEMENT

We are grateful to Professor S. Arihara, Tokushima Bunri University, for his kind gift of α -allo-kainic acid. This work was financially supported in part by a Grant-in-Aid for Scientific Research (No. 01571146) from the Ministry of Education, Science, and Culture of Japan.

REFERENCES AND NOTES

- G. Stork, C. S. Shiner, and J. D. Winkler, J. Am. Chem. Soc., 1982, 104, 310; Y. Hirai, A. Hagiwara, and T. Yamazaki, *Heterocycles*, 1986, 24, 571; Y. Hirai, T. Terada, A. Hagiwara, and T. Yamazaki, Chem. Pharm. Bull., 1988, 36, 1343; A. Alexakis, M. J. Chapdelaine, and G. H. Posner, Tetrahedron Lett., 1978, 4209.
- 2 G. Stork and N. A. Saccomano, Tetrahedron Lett., 1987, 28, 2087.
- 3. Y. Hirai, T. Terada, and T. Yamazaki, J. Am. Chem. Soc., 1988, 110, 958.
- 4. A. Padwa, H. Nimmesgern, and G. S. K. Wong, J. Org. Chem., 1985, 50, 5620.

5. The compound 5 was readily prepared from tryptamine via the amine 16 in 42% overall yield as follows:



- 6. U. Eisner, J. A. Elvidge, and R. P. Linstead, J. Chem. Soc., 1951, 1501.
- All new compounds gave satisfactory 270 Mz ¹H nmr, ir, and high resolution mass spectra and/or elemental analysis: for example, for (-)-11; ¹H nmr (270 MHz, CDCl₃) δ : 1.25 (3H, t, J = 7.1 Hz, OCH₂CH₃), 1.68 (3H, s, COCH₃), 2.68 (1H, dd, J = 7.1 and 16.9 Hz,CH(H)CO₂), 2.85 (1H, dd, J = 4.2 and 16.9 Hz, CH(H)CO₂), 3.09-3.16 (1H, m, CHCH₂CO₂), 3.21-3.33 (2H, m, CHCOMe and NCH(H)CH), 3.39-3.48 (1H, m, NCH(H)CH), 4.13 (2H, q, J = 7.1Hz, CO₂CH₂Me), 4.40 and 4.55 (2H, ABq, J = 14.7 Hz, ArCH₂), 7.22-7.37 (5H, m, ArH); ir (film) v max: 1690, 1730 cm⁻¹; ms (m/z): 303 (M⁺). Anal. Calcd for C₁₇H₂₁NO₄: C, 67.31; H, 6.98; N, 4.62. Found: C, 67.11; H, 6.96; N, 4.32. For (-)-12; ¹H nmr (CDCl₃) δ: 1.23 (3H, t, J = 7.1 Hz, OCH₂CH₃), 1.65 (9H, s, O'Bu), 2.14 (3H, s, COCH₃), 2.30-3.80 (10H, m), 4.12 (2H, q, J = 7.1 Hz, OCH₂Me), 7.10-7.70 (4H, m, ArH), 7.93-8.16 (1H, m, ArH); ir (film) v max:1680, 1728 cm⁻¹. Anal. Calcd for C₂₅H₃₂N₂O₆: C, 65.77; H, 7.07; N, 6.14. Found: C, 65.44; H, 7.05; N, 5.84.
- 8. J. Tsuji, K. Masaoka, and T. Takahashi, Tetrahedron Lett., 1977, 2267.
- 9. Commercially available amine, $[\alpha]_D^{20} + 39^\circ (neat)(ee > 99\%)$, was used.
- 10 An experimental procedure for the cyclization of 9 is as follows: (+)-Phenylethylamine (952 mg, 7.86 mmol) was added dropwise to a stirred solution of 9 (2.38 g, 7.86 mmol) in THF (25 mL) at 0°C. Molecular sieve 3A was added and the mixture was stirred at *ca*. 5°C. After disappearance of the starting material on inspection of its thin layer chromatography, the molecular sieve was filtered off through a Celite column. Usual work-up of the filtrate followed by column chromatography (silica gel 70g, elution with hexane : acetone = 5:1) gave (+)-11 (2.1 g, 6.96 mmol) as a colorless oil.
- 11. The present moderate optical yield would be rationalized by assuming that the contribution of the free energy change in enantio-differentiation would be reduced for the transition state leading to the cyclization into a five-memberd ring as compared to that for six-membered one, becasuse the reaction period for the pyrrolidone was much shorter for completion than that for the piperidine³ at 5°C (2 weeks for the pyrrolidone as against 3 weeks for the piperidine).
- 12. Commercially available amine, $[\alpha]_D^{20}$ -39°(neat)(ee > 99%), was used.
- 13. The chiral column OJ (Daicel Chemical Industries, Ltd.) was used.
- 14. The conversion of kainic acid into the pyrrolidine derivative via the oxidative decarboxylation process has been reported: R. D. Allan, *Tetrahedron Lett.*, **1978**, 2199.
- 15. Determined by hplc using the chiral column AS (Daicel Chemical Industries, Ltd.).
- 16. For the deoxygenation process, see: J. R. Rasmussen, C. J. Slinger, R. J. Kordish, and D. D. N.-Evans, J. Org. Chem., 1981, 46, 4843.
- The synthesis of a framework of the Strychnos alkaloid from N-tryptophylpyrrolidone via the thio-Claisen rearrangement has been reported: S. Takano, M. Hirama, and K. Ogasawara, Tetrahedron Lett., 1982, 23, 881.

Received, 25th October, 1990